WAM
ENVB icon

Warberg Asset Management’s Enveric Biosciences ENVB Stock Holding History

Warberg Asset Management’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5
Closed -$15K – 260
2022
Q1 		$15K Buy
+5
New +$22.1K ﹤0.01% 192

Other funds holding ENVB

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Warberg Asset Management's ENVB Position: Q2 2022 in Review

Warberg Asset Management sold out of Enveric Biosciences (ENVB) in Q2 2022, closing a stake of 5 shares — an estimated $15K sold.

Warberg Asset Management first reported a position in ENVB in Q1 2022 and held it in 1 quarter. The position peaked at $15K in Q1 2022. 21 funds tracked by Wall St. Rank hold ENVB as of Q2 2022.

  • Warberg Asset Management reported no remaining Enveric Biosciences position as of Q2 2022 after selling out during the quarter.
  • Warberg Asset Management sold 5 Enveric Biosciences shares in Q2 2022, an estimated $15K.
  • Warberg Asset Management first reported a position in Enveric Biosciences in Q1 2022 and held it in 1 quarter.
  • Warberg Asset Management's Enveric Biosciences position peaked at $15K in Q1 2022.
  • 21 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2022.

Based on Warberg Asset Management's 13F filing for Q2 2022, filed 11 Aug 2022.